Design Therapeutics
Update in progressDSGN (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Design Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on designing and developing small-molecule therapies for genetic diseases caused by nucleotide repeat expansion. Using its GeneTAC platform, it aims to create disease-modifying candidates for Friedreich ataxia, Myotonic Dystrophy Type-1, Fuchs endothelial corneal dystrophy, and Huntington’s disease. Incorporated in 2017, based in Carlsbad, California.
Company score
- Sentiment
- 0.46
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.26
- Governance
- 0.00
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.08
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.27
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationUnited States
- CEOMr. Pratik Shah Ph.D.
- Founded2017
- Employees55
- Websitewww.designtx.com
Identifiers
- ISINUS25056L1035
- FIGIBBG00SNC49V8
- CUSIP25056L103
- CIK0001807120